DR5/WDR12 balances p65 stability promoting sunitinib resistance in renal cell carcinoma - PubMed
5 hours ago
- #renal cell carcinoma
- #sunitinib resistance
- #NF-κB signaling
- DR5 is upregulated in ccRCC tissues and sunitinib-resistant cells, linked to poor outcomes and resistance.
- DR5 promotes sunitinib resistance by enhancing NF-κB signaling via reduced p65 degradation.
- A positive feedback loop between DR5 and p65 upregulates BCL2, contributing to resistance.
- Targeting the DR5/NF-κB/BCL2 axis sensitizes ccRCC cells to sunitinib in vitro and in vivo.
- High DR5 expression in ccRCC patients correlates with decreased TKI therapy responsiveness.